Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 49

1.

Phase II study of carfilzomib, thalidomide, and low-dose dexamethasone as induction and consolidation in newly diagnosed, transplant eligible patients with multiple myeloma; the Carthadex trial.

Wester R, van der Holt B, Asselbergs E, Zweegman S, Kersten MJ, Vellenga E, van Marwijk Kooy M, de Weerdt O, Minnema M, Lonergan S, Palumbo A, Lokhorst H, Broijl A, Sonneveld P.

Haematologica. 2019 Nov;104(11):2265-2273. doi: 10.3324/haematol.2018.205476. Epub 2019 Apr 4.

2.

Molecular Minimal Residual Disease in Acute Myeloid Leukemia.

Jongen-Lavrencic M, Grob T, Hanekamp D, Kavelaars FG, Al Hinai A, Zeilemaker A, Erpelinck-Verschueren CAJ, Gradowska PL, Meijer R, Cloos J, Biemond BJ, Graux C, van Marwijk Kooy M, Manz MG, Pabst T, Passweg JR, Havelange V, Ossenkoppele GJ, Sanders MA, Schuurhuis GJ, Löwenberg B, Valk PJM.

N Engl J Med. 2018 Mar 29;378(13):1189-1199. doi: 10.1056/NEJMoa1716863.

3.

Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial.

Goldschmidt H, Lokhorst HM, Mai EK, van der Holt B, Blau IW, Zweegman S, Weisel KC, Vellenga E, Pfreundschuh M, Kersten MJ, Scheid C, Croockewit S, Raymakers R, Hose D, Potamianou A, Jauch A, Hillengass J, Stevens-Kroef M, Raab MS, Broijl A, Lindemann HW, Bos GMJ, Brossart P, van Marwijk Kooy M, Ypma P, Duehrsen U, Schaafsma RM, Bertsch U, Hielscher T, Jarari L, Salwender HJ, Sonneveld P.

Leukemia. 2018 Feb;32(2):383-390. doi: 10.1038/leu.2017.211. Epub 2017 Jul 4.

PMID:
28761118
4.

A randomized clinical trial on the effectiveness of an intervention to treat psychological distress and improve quality of life after autologous stem cell transplantation.

Braamse AMJ, van Meijel B, Visser OJ, Boenink AD, Cuijpers P, Eeltink CE, Hoogendoorn AW, van Marwijk Kooy M, van Oppen P, Huijgens PC, Beekman ATF, Dekker J.

Ann Hematol. 2016 Jan;95(1):105-114. doi: 10.1007/s00277-015-2509-6. Epub 2015 Sep 30.

5.

Comparative therapeutic value of post-remission approaches in patients with acute myeloid leukemia aged 40-60 years.

Cornelissen JJ, Versluis J, Passweg JR, van Putten WL, Manz MG, Maertens J, Beverloo HB, Valk PJ, van Marwijk Kooy M, Wijermans PW, Schaafsma MR, Biemond BJ, Vekemans MC, Breems DA, Verdonck LF, Fey MF, Jongen-Lavrencic M, Janssen JJ, Huls G, Kuball J, Pabst T, Graux C, Schouten HC, Gratwohl A, Vellenga E, Ossenkoppele G, Löwenberg B; HOVON; SAKK Leukemia Groups.

Leukemia. 2015 May;29(5):1041-50. doi: 10.1038/leu.2014.332. Epub 2014 Nov 27.

PMID:
25428261
6.

Phase 2 study of carfilzomib, thalidomide, and dexamethasone as induction/consolidation therapy for newly diagnosed multiple myeloma.

Sonneveld P, Asselbergs E, Zweegman S, van der Holt B, Kersten MJ, Vellenga E, van Marwijk-Kooy M, Broyl A, de Weerdt O, Lonergan S, Palumbo A, Lokhorst H.

Blood. 2015 Jan 15;125(3):449-56. doi: 10.1182/blood-2014-05-576256. Epub 2014 Nov 14.

7.

Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial.

Scheid C, Sonneveld P, Schmidt-Wolf IG, van der Holt B, el Jarari L, Bertsch U, Salwender H, Zweegman S, Blau IW, Vellenga E, Weisel K, Pfreundschuh M, Jie KS, Neben K, van de Velde H, Duehrsen U, Schaafsma MR, Lindemann W, Kersten MJ, Peter N, Hänel M, Croockewit S, Martin H, Wittebol S, Bos GM, van Marwijk-Kooy M, Wijermans P, Goldschmidt H, Lokhorst HM.

Haematologica. 2014 Jan;99(1):148-54. doi: 10.3324/haematol.2013.087585. Epub 2013 Aug 30.

8.

[A man with neutropenic fever].

Ham JC, Ruijs GJ, van Marwijk Kooy MR.

Ned Tijdschr Geneeskd. 2013;157(12):A5997. Dutch.

PMID:
23515043
9.

Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial.

Sonneveld P, Schmidt-Wolf IG, van der Holt B, El Jarari L, Bertsch U, Salwender H, Zweegman S, Vellenga E, Broyl A, Blau IW, Weisel KC, Wittebol S, Bos GM, Stevens-Kroef M, Scheid C, Pfreundschuh M, Hose D, Jauch A, van der Velde H, Raymakers R, Schaafsma MR, Kersten MJ, van Marwijk-Kooy M, Duehrsen U, Lindemann W, Wijermans PW, Lokhorst HM, Goldschmidt HM.

J Clin Oncol. 2012 Aug 20;30(24):2946-55. doi: 10.1200/JCO.2011.39.6820. Epub 2012 Jul 16. Erratum in: J Clin Oncol. 2012 Oct 10;30(29):3654.

PMID:
22802322
10.

Comparative analysis of the value of allogeneic hematopoietic stem-cell transplantation in acute myeloid leukemia with monosomal karyotype versus other cytogenetic risk categories.

Cornelissen JJ, Breems D, van Putten WL, Gratwohl AA, Passweg JR, Pabst T, Maertens J, Beverloo HB, van Marwijk Kooy M, Wijermans PW, Biemond BJ, Vellenga E, Verdonck LF, Ossenkoppele GJ, Löwenberg B.

J Clin Oncol. 2012 Jun 10;30(17):2140-6. doi: 10.1200/JCO.2011.39.6499. Epub 2012 May 7.

PMID:
22564995
11.

Intensive chemotherapy to improve outcome in patients with acute lymphoblastic leukemia over the age of 40: a phase II study for efficacy and feasibility by HOVON.

Daenen S, van der Holt B, Dekker AW, Willemze R, Rijneveld AW, Biemond BJ, Muus P, van de Loosdrecht AA, Schouten HC, van Marwijk Kooy M, Breems DA, Demuynck H, Maertens J, Wijermans PW, Wittebol S, de Klerk EW, Cornelissen JJ; HOVON; Dutch-Belgian Cooperative Group for Hematological Oncology.

Leukemia. 2012 Jul;26(7):1726-9. doi: 10.1038/leu.2012.53. Epub 2012 Feb 23. No abstract available.

PMID:
22358264
12.

Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme.

van der Helm LH, Alhan C, Wijermans PW, van Marwijk Kooy M, Schaafsma R, Biemond BJ, Beeker A, Hoogendoorn M, van Rees BP, de Weerdt O, Wegman J, Libourel WJ, Luykx-de Bakker SA, Minnema MC, Brouwer RE, Croon-de Boer F, Eefting M, Jie KS, van de Loosdrecht AA, Koedam J, Veeger NJ, Vellenga E, Huls G.

Br J Haematol. 2011 Dec;155(5):599-606. doi: 10.1111/j.1365-2141.2011.08893.x. Epub 2011 Oct 8.

PMID:
21981697
13.

Effect of thalidomide with melphalan and prednisone on health-related quality of life (HRQoL) in elderly patients with newly diagnosed multiple myeloma: a prospective analysis in a randomized trial.

Verelst SG, Termorshuizen F, Uyl-de Groot CA, Schaafsma MR, Ammerlaan AH, Wittebol S, Sinnige HA, Zweegman S, van Marwijk Kooy M, van der Griend R, Lokhorst HM, Sonneveld P, Wijermans PW; Dutch-Belgium Hemato-Oncology Cooperative Group (HOVON).

Ann Hematol. 2011 Dec;90(12):1427-39. doi: 10.1007/s00277-011-1224-1. Epub 2011 Apr 7.

PMID:
21472373
14.

Intensified alemtuzumab-CHOP therapy for peripheral T-cell lymphoma.

Kluin-Nelemans HC, van Marwijk Kooy M, Lugtenburg PJ, van Putten WL, Luten M, Oudejans J, van Imhoff GW.

Ann Oncol. 2011 Jul;22(7):1595-600. doi: 10.1093/annonc/mdq635. Epub 2011 Jan 6.

15.

Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study.

Wijermans P, Schaafsma M, Termorshuizen F, Ammerlaan R, Wittebol S, Sinnige H, Zweegman S, van Marwijk Kooy M, van der Griend R, Lokhorst H, Sonneveld P; Dutch-Belgium Cooperative Group HOVON.

J Clin Oncol. 2010 Jul 1;28(19):3160-6. doi: 10.1200/JCO.2009.26.1610. Epub 2010 Jun 1.

PMID:
20516439
16.

[Monoclonal B-cell lymphocytosis: physiological entity or preliminary stage of chronic lymphocytic leukaemia?].

Schindhelm RK, van Marwijk Kooy MR, Coenen JL, Huijgens PC, Kuiper-Kramer PA.

Ned Tijdschr Geneeskd. 2010;154:A1520. Review. Dutch.

PMID:
20482911
17.

Efficacy of escalated imatinib combined with cytarabine in newly diagnosed patients with chronic myeloid leukemia.

Deenik W, Janssen JJ, van der Holt B, Verhoef GE, Smit WM, Kersten MJ, Daenen SM, Verdonck LF, Ferrant A, Schattenberg AV, Sonneveld P, van Marwijk Kooy M, Wittebol S, Willemze R, Wijermans PW, Beverloo HB, Löwenberg B, Valk PJ, Ossenkoppele GJ, Cornelissen JJ.

Haematologica. 2010 Jun;95(6):914-21. doi: 10.3324/haematol.2009.016766. Epub 2009 Dec 16.

18.

A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma.

Lokhorst HM, van der Holt B, Zweegman S, Vellenga E, Croockewit S, van Oers MH, von dem Borne P, Wijermans P, Schaafsma R, de Weerdt O, Wittebol S, Delforge M, Berenschot H, Bos GM, Jie KS, Sinnige H, van Marwijk-Kooy M, Joosten P, Minnema MC, van Ammerlaan R, Sonneveld P; Dutch-Belgian Hemato-Oncology Group (HOVON).

Blood. 2010 Feb 11;115(6):1113-20. doi: 10.1182/blood-2009-05-222539. Epub 2009 Oct 30.

PMID:
19880501
19.

Quality of life after successful treatment of early-stage Hodgkin's lymphoma: 10-year follow-up of the EORTC-GELA H8 randomised controlled trial.

Heutte N, Flechtner HH, Mounier N, Mellink WA, Meerwaldt JH, Eghbali H, van't Veer MB, Noordijk EM, Kluin-Nelemans JC, Lampka E, Thomas J, Lugtenburg PJ, Viterbo L, Carde P, Hagenbeek A, van der Maazen RW, Smit WG, Brice P, van Marwijk Kooy M, Baars JW, Poortmans P, Tirelli U, Leeksma OC, Tomsic R, Feugier P, Salles G, Gabarre J, Kersten MJ, Van Den Neste E, Creemers GJ, Gaillard I, Meijnders P, Tertian G, Reman O, Muller HP, Troncy J, Blanc M, Schroyens W, Voogt PJ, Wijermans P, Rieux C, Fermé C, Henry-Amar M; EORTC-GELA H8 Trial Group.

Lancet Oncol. 2009 Dec;10(12):1160-70. doi: 10.1016/S1470-2045(09)70258-X. Epub 2009 Oct 12.

PMID:
19828373
20.

High-dose daunorubicin in older patients with acute myeloid leukemia.

Löwenberg B, Ossenkoppele GJ, van Putten W, Schouten HC, Graux C, Ferrant A, Sonneveld P, Maertens J, Jongen-Lavrencic M, von Lilienfeld-Toal M, Biemond BJ, Vellenga E, van Marwijk Kooy M, Verdonck LF, Beck J, Döhner H, Gratwohl A, Pabst T, Verhoef G; Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON); German AML Study Group (AMLSG); Swiss Group for Clinical Cancer Research (SAKK) Collaborative Group.

N Engl J Med. 2009 Sep 24;361(13):1235-48. doi: 10.1056/NEJMoa0901409. Erratum in: N Engl J Med. 2010 Mar 25;362(12):1155. Dosage error in published abstract; MEDLINE/PubMed abstract corrected; Dosage error in article text.

21.

Myeloablative allogeneic versus autologous stem cell transplantation in adult patients with acute lymphoblastic leukemia in first remission: a prospective sibling donor versus no-donor comparison.

Cornelissen JJ, van der Holt B, Verhoef GE, van't Veer MB, van Oers MH, Schouten HC, Ossenkoppele G, Sonneveld P, Maertens J, van Marwijk Kooy M, Schaafsma MR, Wijermans PW, Biesma DH, Wittebol S, Voogt PJ, Baars JW, Zachée P, Verdonck LF, Löwenberg B, Dekker AW; Dutch-Belgian HOVON Cooperative Group.

Blood. 2009 Feb 5;113(6):1375-82. doi: 10.1182/blood-2008-07-168625. Epub 2008 Nov 6.

PMID:
18988865
22.

Dose-finding study of imatinib in combination with intravenous cytarabine: feasibility in newly diagnosed patients with chronic myeloid leukemia.

Deenik W, van der Holt B, Verhoef GE, Smit WM, Kersten MJ, Kluin-Nelemans HC, Verdonck LF, Ferrant A, Schattenberg AV, Janssen JJ, Sonneveld P, van Marwijk Kooy M, Wittebol S, Willemze R, Wijermans PW, Westveer PH, Beverloo HB, Valk P, Löwenberg B, Ossenkoppele GJ, Cornelissen JJ.

Blood. 2008 Mar 1;111(5):2581-8. doi: 10.1182/blood-2007-08-107482. Epub 2008 Jan 2.

PMID:
18172005
23.

Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma.

Lokhorst HM, Schmidt-Wolf I, Sonneveld P, van der Holt B, Martin H, Barge R, Bertsch U, Schlenzka J, Bos GM, Croockewit S, Zweegman S, Breitkreutz I, Joosten P, Scheid C, van Marwijk-Kooy M, Salwender HJ, van Oers MH, Schaafsma R, Naumann R, Sinnige H, Blau I, Delforge M, de Weerdt O, Wijermans P, Wittebol S, Duersen U, Vellenga E, Goldschmidt H; Dutch-Belgian HOVON; German GMMG.

Haematologica. 2008 Jan;93(1):124-7. doi: 10.3324/haematol.11644. Erratum in: Haematologica. 2008 Mar;93(3):480. Verhoef, Gregor [removed]; Delforge, Michel [added]; Breitkreuz, Iris [corrected to Breitkreutz, Iris].

24.

Failure of CHOP with rituximab for lymphomatoid granulomatosis.

Oosting-Lenstra SF, van Marwijk Kooy M.

Neth J Med. 2007 Dec;65(11):442-7.

25.

Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom?

Cornelissen JJ, van Putten WL, Verdonck LF, Theobald M, Jacky E, Daenen SM, van Marwijk Kooy M, Wijermans P, Schouten H, Huijgens PC, van der Lelie H, Fey M, Ferrant A, Maertens J, Gratwohl A, Lowenberg B.

Blood. 2007 May 1;109(9):3658-66. Epub 2007 Jan 9.

PMID:
17213292
26.

Short intensive sequential therapy followed by autologous stem cell transplantation in adult Burkitt, Burkitt-like and lymphoblastic lymphoma.

van Imhoff GW, van der Holt B, MacKenzie MA, Ossenkoppele GJ, Wijermans PW, Kramer MH, van 't Veer MB, Schouten HC, van Marwijk Kooy M, van Oers MH, Raemaekers JM, Sonneveld P, Meulendijks LA, Kluin PM, Kluin-Nelemans HC, Verdonck LF; Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON).

Leukemia. 2005 Jun;19(6):945-52.

PMID:
15800666
27.

Observer variability in the assessment of clinical probability in patients with suspected pulmonary embolism.

Leclercq MG, Kruip MJ, Mac Gillavry MR, Van Marwijk Kooy M, Büller HR.

J Thromb Haemost. 2004 Jul;2(7):1204-6. No abstract available.

28.

Florid granulomatous reaction in Epstein-Barr virus-positive nonendemic Burkitt lymphomas: report of four cases.

Haralambieva E, Rosati S, van Noesel C, Boers E, van Marwijk Kooy M, Schuuring E, Kluin P.

Am J Surg Pathol. 2004 Mar;28(3):379-83.

PMID:
15104301
29.

A woman with a swollen, erythematous and tender thigh.

Nauta S, van Marwijk Kooy M, van der Ven AJ.

Neth J Med. 2003 Sep;61(9):290, 303. No abstract available.

30.

Cost-utility analysis of survival with epoetin-alfa versus placebo in stage IV breast cancer.

Martin SC, Gagnon DD, Zhang L, Bokemeyer C, Van Marwijk Kooy M, van Hout B.

Pharmacoeconomics. 2003;21(16):1153-69.

PMID:
14594437
31.

Ruling out clinically suspected pulmonary embolism by assessment of clinical probability and D-dimer levels: a management study.

Leclercq MG, Lutisan JG, van Marwijk Kooy M, Kuipers BF, Oostdijk AH, van der Leur JJ, Büller HR.

Thromb Haemost. 2003 Jan;89(1):97-103.

PMID:
12540959
32.

Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study.

Segeren CM, Sonneveld P, van der Holt B, Vellenga E, Croockewit AJ, Verhoef GE, Cornelissen JJ, Schaafsma MR, van Oers MH, Wijermans PW, Fibbe WE, Wittebol S, Schouten HC, van Marwijk Kooy M, Biesma DH, Baars JW, Slater R, Steijaert MM, Buijt I, Lokhorst HM; Dutch-Belgian Hemato-Oncology Cooperative Study Group.

Blood. 2003 Mar 15;101(6):2144-51. Epub 2002 Nov 27.

PMID:
12456509
34.

Changes in perfusion scintigraphy in the first days of heparin therapy in patients with acute pulmonary embolism.

de Groot MR, Oostdijk AH, Engelage AH, van Marwijk Kooy M, Büller HR.

Eur J Nucl Med. 2000 Oct;27(10):1481-6.

PMID:
11083536
35.

Reactions and platelet increments after transfusion of platelet concentrates in plasma or an additive solution: a prospective, randomized study.

de Wildt-Eggen J, Nauta S, Schrijver JG, van Marwijk Kooy M, Bins M, van Prooijen HC.

Transfusion. 2000 Apr;40(4):398-403.

PMID:
10773049
36.

Value of chest X-ray combined with perfusion scan versus ventilation/perfusion scan in acute pulmonary embolism.

de Groot MR, Turkstra F, van Marwijk Kooy M, Oostdijk AH, van Beek EJ, Büller HR.

Thromb Haemost. 2000 Mar;83(3):412-5.

PMID:
10744146
37.

The use of a rapid D-dimer blood test in the diagnostic work-up for pulmonary embolism: a management study.

de Groot MR, van Marwijk Kooy M, Pouwels JG, Engelage AH, Kuipers BF, Büller HR.

Thromb Haemost. 1999 Dec;82(6):1588-92.

PMID:
10613639
38.

Vincristine, doxorubicin and dexamethasone (VAD) administered as rapid intravenous infusion for first-line treatment in untreated multiple myeloma.

Segeren CM, Sonneveld P, van der Holt B, Baars JW, Biesma DH, Cornellissen JJ, Croockewit AJ, Dekker AW, Fibbe WE, Löwenberg B, van Marwijk Kooy M, van Oers MH, Richel DJ, Schouten HC, Vellenga E, Verhoef GE, Wijermans PW, Wittebol S, Lokhorst HM.

Br J Haematol. 1999 Apr;105(1):127-30.

PMID:
10233375
39.

Induction therapy with vincristine, adriamycin, dexamethasone (VAD) and intermediate-dose melphalan (IDM) followed by autologous or allogeneic stem cell transplantation in newly diagnosed multiple myeloma.

Lokhorst HM, Sonneveld P, Cornelissen JJ, Joosten P, van Marwijk Kooy M, Meinema J, Nieuwenhuis HK, van Oers MH, Richel DJ, Segeren CN, Veth G, Verdonck LF, Wijermans PW.

Bone Marrow Transplant. 1999 Feb;23(4):317-22.

40.

Use of a heparin nomogram for treatment of patients with venous thromboembolism in a community hospital.

de Groot MR, Büller HR, ten Cate JW, van Marwijk Kooy M.

Thromb Haemost. 1998 Jul;80(1):70-3.

PMID:
9684788
41.

Intermediate-dose melphalan (IDM) combined with G-CSF (filgrastim) is an effective and safe induction therapy for autologous stem cell transplantation in multiple myeloma.

Lokhorst HM, Sonneveld P, Wijermans PW, van Marwijk Kooy M, Meuwissen OJ, van Oers RH, van der Griend R, Dekker AW.

Br J Haematol. 1996 Jan;92(1):44-8.

PMID:
8562409
42.

A patient with multiple myeloma and respiratory insufficiency due to accumulation of paraprotein in the alveolar space.

Meijer WG, Van Marwijk Kooy M, Laddé BE.

Br J Haematol. 1994 Jul;87(3):663-5.

PMID:
7993818
43.

UVB radiation exposes fibrinogen binding sites on platelets by activating protein kinase C via reactive oxygen species.

van Marwijk Kooy M, Akkerman JW, van Asbeck S, Borghuis L, van Prooijen HC.

Br J Haematol. 1993 Feb;83(2):253-8.

PMID:
8457474
44.

Mastocytosis and Sjögren's syndrome.

Bac DJ, van Marwijk Kooy M.

Ann Rheum Dis. 1992 Feb;51(2):277-8.

45.

Use of leukocyte-depleted platelet concentrates for the prevention of refractoriness and primary HLA alloimmunization: a prospective, randomized trial.

van Marwijk Kooy M, van Prooijen HC, Moes M, Bosma-Stants I, Akkerman JW.

Blood. 1991 Jan 1;77(1):201-5.

PMID:
1984797
46.

Irradiation of platelets with UV-B light exposes fibrinogen binding sites via an intracellular mechanism.

van Marwijk Kooy M, Borghuis L, van Prooijen HC, Aarts-Riemens MI, Akkerman JW.

Br J Haematol. 1990 Dec;76(4):531-6.

PMID:
2265116
47.

Evaluation of a new UVB source for irradiation of platelet concentrates.

van Prooijen HC, van Marwijk Kooy M, van Weelden H, Aarts-Riemens MI, Borghuis L, Akkerman JW.

Br J Haematol. 1990 Aug;75(4):573-7.

PMID:
2145030
48.

Filtration. A method to prepare white cell-poor platelet concentrates with optimal preservation of platelet viability.

van Marwijk Kooy M, van Prooijen HC, Borghuis L, Moes M, Akkerman JW.

Transfusion. 1990 Jan;30(1):34-8.

PMID:
2296787
49.

[Prevention of HLA alloimmunization due to platelet transfusion].

van Marwijk Kooy M, Brand A, Sintnicolaas K, van Prooijen HC.

Ned Tijdschr Geneeskd. 1988 Apr 23;132(17):758-61. Dutch. No abstract available.

PMID:
3374659

Supplemental Content

Loading ...
Support Center